Global Depression Drugs Market is Driven by Growing Generic Drug Market and Government Initiatives to Educate People

SAN FRANCISCO, July 26, 2017 -- Global Depression Drug Market published by Variant Market Research is expected to reach $18 billion by 2024 from $15 billion in 2016; growing at a CAGR of 2.6% from 2016 to 2024. By geography, Asia-Pacific and Europe are expected to grow at a CAGR of 3.2% and 2.7%, respectively, during the forecast period.

Get full access of this report @ https://www.variantmarketresearch.com/report-categories/pharmaceuticals/depression-drugs-market

The key factors driving the growth of the market include, various government initiations in increasing awareness on depression, elevating generic drug market, and rising geriatric population globally. Furthermore, increasing investments in research & developments and market expansion would provide growth opportunities for the players. Though, social stigma and non-availability of trained healthcare providers especially in rural and remote areas may hinder the growth of the market.

The global depression drugs market is bifurcated into two major segments which include, product type, and application. By product type, the market is sub-segmented into Selective Serotonin Reuptake Inhibitors (SSRIs), Atypical Antipsychotics, Tricyclic Antidepressants, Tetracyclic Antidepressants (TeCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Benzodiazepines, Monoamine Oxidase Inhibitors, and others. Among them, SNRIs dominated the market accounting for more than one fourth of the total depression drugs market share in 2016. Geographically, the market is categorized into North America, Europe, Asia-Pacific and Rest of the world.

Get PDF copy of this report @ https://www.variantmarketresearch.com/report-categories/pharmaceuticals/depression-drugs-market/sample-request

North America held the largest share of the market with 37.2% in 2016; driven by the presence of large consumer base suffering from various kinds of depression and fretfulness disorders. Europe, which holds the second largest market with a total market share of 32.6%. In terms of growth, Asia-Pacific is to attain the fastest CAGR of 3.2% during the forecast period, owing to augmented demand from emerging countries such as China, Japan, and Australia. Increasing consumer awareness regarding benefits of depression drug would provide several growth opportunities for the market in the coming years.

The major key players in the depression drugs market include, Novartis, H. Lundbeck, Forest Laboratories, Merck & Co., AstraZeneca, SK Biopharmaceuticals, Naurex, GlaxoSmithKline, Eli Lilly and Co., and Pfizer, among others.

Table of Contents

Chapter 1. Prefix
     1.1. Market Scope
     1.2. Report Description
     1.3. Research Methodology
           1.3.1 Primary Research
           1.3.2 Secondary Research
           1.3.3 In-house Data Modeling
Chapter 2. Executive Summary
Chapter 3. Market Outline
     3.1 Market Inclination, Trend, Outlook and Viewpoint
     3.2 Market Share Analysis: Company’s Competitive Scenario
     3.3 Value Chain Analysis
     3.4 Market Dynamics
            3.4.1 Drivers
                 3.4.1.1 Impact Analysis
           3.4.2. Restraints
                 3.4.2.1 Impact Analysis
           3.4.3 Opportunities
     3.5 Porter’s five forces analysis
           3.5.1 Factors Impact Analysis    ….

Chapter 7. Company Profiles
     7.1 H.Lundbeck, Merck & Co.
     7.2 SK Biopharmaceuticals
     7.3 Novartis
     7.4 AstraZeneca
     7.5 Forest Laboratories
     7.6 Naurex
     7.7 GlaxoSmithKline
     7.8 Eli Lilly and Co.

About Variant Market Research

Variant Market Research offers syndicated and customized reports to fulfill clients' objectives. We also provide customized data pack proposing market sizing in an Excel/PDF/PowerPoint or Word format as per the requirement of clients. We cover several industry domains, namely Semiconductor & Electronics, Consumer Electronics, Information and Communication Technology, Automotive, Consumer Goods, Food & Beverages, Pharmaceuticals, Medical Devices, Chemicals, Industrial, Mining Equipment, Automation, Manufacturing, Construction, Energy & Power, Defense & Aerospace and Banking, Financial services and Insurance (BFSI). Our expertise are data triangulation, competitor benchmarking, parent market benchmarking, estimating market size and forecast of the market from 2016 to 2024.

For further information, visit www.variantmarketresearch.com

You can connect with us on LinkedIn here @ https://www.linkedin.com/company/variant-market-research

Kailas Disale

Executive at Variant Market Research.

Tel: +1-415-680-2785

Email: [email protected]  

Email: [email protected]